Impact of Sensor Technology in Knee OA
Launched by OPUM TECHNOLOGIES US LTD · Jan 24, 2022
Trial Information
Current as of May 06, 2025
Unknown status
Keywords
ClinConnect Summary
BACKGROUND:
Knee osteoarthritis (OA) is a significant problem in the adult population. With a prevalence of 10-13% in individuals over age 60,(4) knee OA results in a significant reduction in quality of life and increased economic costs to both the individual with knee OA and the medical system as a whole.
Exercise is a key component of management of knee OA, resulting in decreased pain and increased function.(3) Potential barriers to exercise in subjects with knee OA is lack of motivation or professional support.(5) Both of these barriers can be addressed with remote patient monitoring. ...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Pain score \> 12.5 KOOS
- • BMI \< 35
- • Own a compatible mobile phone?
- • Able to operate Bluetooth technology?
- • Diagnosis of unilateral femoro-tibial knee OA
- Exclusion Criteria:
- • History of lower extremity total joint arthroplasty? (in affected knee)
- • Current uncontrolled cardiovascular disease?
- • Other pathology? Ex: Parkinson's, stroke, multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), or other knee diseases (Paget, osteonecrosis, etc.)
About Opum Technologies Us Ltd
Opum Technologies US Ltd. is a pioneering clinical trial sponsor dedicated to advancing medical research through innovative technology solutions. Focused on enhancing patient outcomes and streamlining the drug development process, Opum leverages cutting-edge data analytics and real-time monitoring to optimize clinical trials. With a commitment to compliance and ethical standards, the company collaborates with healthcare professionals and research institutions to facilitate robust clinical studies that address unmet medical needs. Through its expertise and forward-thinking approach, Opum Technologies strives to contribute significantly to the evolution of healthcare and therapeutic advancements.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Chicago, Illinois, United States
Patients applied
Trial Officials
Prakash Jayabalan, MD, PhD
Principal Investigator
Shirley Ryan AbilityLab; Northwestern University Feinberg School of Medicine
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials